Advertisement

Topics

BMS boosts immuno-oncology with $2.3bn IFM buy

07:47 EDT 4 Aug 2017 | PMLIVE

Boston-based group will operate as a subsidiary of BMS

Original Article: BMS boosts immuno-oncology with $2.3bn IFM buy

NEXT ARTICLE

More From BioPortfolio on "BMS boosts immuno-oncology with $2.3bn IFM buy"

Quick Search
Advertisement